Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan by Simonetti, Giacomo D et al.
Pediatr Nephrol (2006) 21: 1329–1330
DOI 10.1007/s00467-006-0162-y
LETTER TO THE EDITORS
Giacomo D. Simonetti . Thomas Baumann .
Jana M. Pachlopnik . Rodo O. von Vigier .
Mario G. Bianchetti
Non-lethal fetal toxicity of the angiotensin receptor blocker
candesartan
Received: 9 February 2006 / Revised: 2 March 2006 / Accepted: 2 March 2006 / Published online: 29 June 2006
# IPNA 2006
Angiotensin receptor blockers are potent antihypertensive
drugs with very few side effects [1, 2]. No association has
been documented between use of angiotensin receptor
blockers during the first trimester of gestation and con-
genital defects. However, there are several reports of
malformations and physiologic disturbances, mostly with
lethal outcome, in infants exposed to these drugs during
the second and third trimesters, as recently reviewed [3,
4]. We report the adverse long-term sequelae noted in an
infant following maternal treatment with an angiotensin
receptor blocker.
A 39-year old woman on treatment with candesartan
cilexetil 16 mg once a day [5] for mild essential hyper-
tension became pregnant but the drug was not discon-
tinued. At 31 weeks a male boy weighing 1.65 kg was
delivered by cesarian section. The physical examination
disclosed climb contractures, skull hypoplasia with mi-
crocephaly (head circumference 0.265 m) and moderately
underdeveloped calvarial bones. The child developed
immediate respiratory distress (treated with oxygen,
exogenous surfactant and mechanical respiratory support),
arterial hypotension (treated with dopamine and epineph-
rine), and moderate oliguria (creatinine up to 281 μmol/l,
urea up to 15.6 mmol/l and a pathologically increased
urinary protein to creatinine ratio of 739 mg/mmol; upper
reference 50). His conditions improved during the second
week of postnatal life. However, a tendency towards
arterial hypertension (mean blood pressure 75–80 mm Hg;
upper reference 68) was noted, requiring treatment with
the calcium channel blocker amlodipine once a day during
6 weeks. Routine chromosome analysis revealed a normal
male karyotype.
The boy is currently 34 months of age. Body weight is
11.1 kg (−2.8 SDS), length 0.901 m (−1.5 SDS), head
circumference 0.481 m (−2 SDS) and blood pressure slightly
elevated (approximately 110/70 mm Hg; upper reference
106/66) and the calvarial bones normally developed. His
cognitive and especially his linguistic development are
moderately retarded. The physical examination is otherwise
normal. Plasma creatinine (36 μmol/l) and urea (6.0 mmol/l)
are normal. The urinary protein to creatinine ratio is slightly
increased (29 mg/mmol, upper reference 20). Renal ultra-
sound study demonstrates rather small hyperechogenic
kidneys and loss of corticomedullary differentiation.
In conclusion during pregnancy the use of drugs that
block the renin–angiotensin–aldosterone system, namely
angiotensin receptor blockers [3, 4] and converting enzyme
inhibitors [4, 6], is strongly cautioned against. Infants
surviving the exposition to these agents during the second
and third trimesters tend to a chronic kidney disease and a
developmental delay. A corresponding long-term follow up
is warranted.
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